Drug intelligence / Profile preview

mAb9

Development stage: Preclinical
Lead developer: Stainwei Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

mAb9 is a monoclonal antibody currently in the preclinical stage of development by Stainwei Biotechnology (Suzhou Stainwei Biotech Inc.). According to the company's pipeline information, the drug is being investigated for a 'new indication,' although the specific biological target and the exact therapeutic area have not been publicly disclosed. It is part of a series of early-stage antibody candidates (mAb4 through mAb10) in Stainwei's portfolio targeting various oncology and inflammatory conditions.

Beyond the preview

Go deeper on mAb9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb9.

Explore the full profile